Skip to Content

Vimizim Approval History

  • FDA approved: Yes (First approved February 14th, 2014)
  • Brand name: Vimizim
  • Generic name: elosufase alfa
  • Dosage form: Injection
  • Company: BioMarin Pharmaceutical Inc.
  • Treatment for: Mucopolysaccharidosis Type IVA

Vimizim (elosufase alfa) is an enzyme replacement therapy for patients with Mucopolysaccharidosis Type IVA (Morquio A syndrome).

Development History and FDA Approval Process for Vimizim

Feb 16, 2014Approval FDA Approves Vimizim to Treat Mucopolysaccharidosis Type IVA
Nov 20, 2013FDA Advisory Committee Recommends Approval of Vimizim for Morquio A Syndrome

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.